SG11201908129PA - LIQUID BIOPSY FOR cfRNA - Google Patents
LIQUID BIOPSY FOR cfRNAInfo
- Publication number
- SG11201908129PA SG11201908129PA SG11201908129PA SG11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- boulevard
- response
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
International Patent Classification: C12Q 1/68 (2018.01) C12Q 1/6806 (2018.01) (21) International Application Number: PCT/US2018/022747 (22) International Filing Date: 15 March 2018 (15.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/473,273 17 March 2017 (17.03.2017) US 62/522,509 20 June 2017 (20.06.2017) US 62/593,534 01 December 2017 (01.12.2017) US (71) Applicant: NANTOMICS, LLC [US/US]; 9920 Jefferson Boulevard, Culver City, California 90232 (US). (72) Inventors: DANENBERG, Kathleen; 9920 Jeffer- son Boulevard, Culver City, California 90232 (US). RABIZADEH, Shahrooz; 9920 Jefferson Boulevard, Cul- ver City, California 90232 (US). USHER, Joshua; 9920 Jefferson Boulevard, Culver City, California 90232 (US). JAIMES, Yolanda; 9920 Jefferson Boulevard, Culver City, California 90232 (US). (74) Agent: FESSENMAIER, Martin et al.; UMBERG ZIPSER LLP, 1920 Main Street, Suite 750, Irvine, Califor- nia 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). immunotherapy Response (54) Title: LIQUID BIOPSY FOR cfRNA Response No Response O N 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT iiimmomiolollmonolomolomonoolomioluovoil# (10) International Publication Number WO 2018/170329 Al Figure 5B (57) : cfRNA is used to identify and quantitate expression levels of disease related genes and further allows for non-invasive monitoring of changes in such genes. Moreover, quantitative analysis of disease related genes will enable prediction of treatment response where the treatment is dependent on the presence of the disease related gene. [Continued on next page] WO 2018/170329 Al MIDEDIMOMMIDIREEMOMMEIMEMOICHIMEMOIMIE Published: — with international search report (Art. 21(3)) with amended claims (Art. 19(1))
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473273P | 2017-03-17 | 2017-03-17 | |
| US201762522509P | 2017-06-20 | 2017-06-20 | |
| US201762593534P | 2017-12-01 | 2017-12-01 | |
| PCT/US2018/022747 WO2018170329A1 (en) | 2017-03-17 | 2018-03-15 | LIQUID BIOPSY FOR cfRNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908129PA true SG11201908129PA (en) | 2019-10-30 |
Family
ID=63523347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908129P SG11201908129PA (en) | 2017-03-17 | 2018-03-15 | LIQUID BIOPSY FOR cfRNA |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200102618A1 (en) |
| EP (1) | EP3596231A1 (en) |
| JP (1) | JP2020511137A (en) |
| KR (1) | KR20190129094A (en) |
| CN (1) | CN110431238A (en) |
| AU (1) | AU2018234821A1 (en) |
| CA (1) | CA3056700A1 (en) |
| IL (1) | IL269402A (en) |
| SG (1) | SG11201908129PA (en) |
| WO (1) | WO2018170329A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628057A4 (en) * | 2017-05-03 | 2020-05-13 | Nantomics, LLC | TUMOR VS. MATCHED NORMAL cfRNA |
| CN110621790A (en) * | 2017-05-10 | 2019-12-27 | 南托米克斯有限责任公司 | Circulating RNA for detecting, predicting and monitoring cancer |
| US11821043B2 (en) | 2017-08-17 | 2023-11-21 | Nantomics Llc | Dynamic changes in circulating free RNA of neural tumors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1907424T3 (en) * | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| DK3290530T3 (en) * | 2009-02-18 | 2020-12-07 | Streck Inc | PRESERVATION OF CELL-FREE NUCLEIC ACIDS |
| US8841418B2 (en) * | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| EP2878678A1 (en) * | 2013-12-02 | 2015-06-03 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | RNA-biomarkers for diagnosis of prostate cancer |
| RU2707530C2 (en) * | 2014-01-02 | 2019-11-27 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Cancer tumour response determinants for immunotherapy |
| CR20170143A (en) * | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME |
| WO2016077709A1 (en) * | 2014-11-14 | 2016-05-19 | Liquid Genomics, Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
| JP2018514550A (en) * | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Treatment of PD-L1 negative melanoma using anti-PD-1 antibody and anti-CTLA-4 antibody |
-
2018
- 2018-03-15 CN CN201880018779.6A patent/CN110431238A/en not_active Withdrawn
- 2018-03-15 JP JP2019550590A patent/JP2020511137A/en not_active Abandoned
- 2018-03-15 AU AU2018234821A patent/AU2018234821A1/en not_active Withdrawn
- 2018-03-15 WO PCT/US2018/022747 patent/WO2018170329A1/en active Search and Examination
- 2018-03-15 EP EP18766798.5A patent/EP3596231A1/en not_active Withdrawn
- 2018-03-15 US US16/494,683 patent/US20200102618A1/en not_active Abandoned
- 2018-03-15 KR KR1020197030315A patent/KR20190129094A/en not_active Application Discontinuation
- 2018-03-15 CA CA3056700A patent/CA3056700A1/en not_active Withdrawn
- 2018-03-15 SG SG11201908129P patent/SG11201908129PA/en unknown
-
2019
- 2019-09-16 IL IL26940219A patent/IL269402A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200102618A1 (en) | 2020-04-02 |
| JP2020511137A (en) | 2020-04-16 |
| AU2018234821A1 (en) | 2019-09-26 |
| KR20190129094A (en) | 2019-11-19 |
| IL269402A (en) | 2019-11-28 |
| CA3056700A1 (en) | 2018-09-20 |
| CN110431238A (en) | 2019-11-08 |
| EP3596231A1 (en) | 2020-01-22 |
| WO2018170329A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201907162TA (en) | Methods for cell-type specific profiling to identify drug targets | |
| SG11201811405QA (en) | Improved differentiation method | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201901006RA (en) | Systems and methods for enhanced organizational transparency using a credit chain | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
| SG11201908847TA (en) | Apparatuses, systems and methods for imaging flow cytometry | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201908127WA (en) | Method for producing multispecific antibodies | |
| SG11201806401YA (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901991QA (en) | Methods of detecting per cell pd-l1 expression and uses thereof | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders |